Frailty has emerged as a major public health concern in aging populations, particularly among individuals with Alzheimer's disease (AD), where it exacerbates adverse outcomes and signals dementia progression. While research on frailty in AD has grown rapidly, a thorough analysis of key research hotspots and trends remains insufficient.
Objective
This study employs bibliometric methods to systematically explore core themes, identify potential frontiers and emerging directions in this field.
Methods
On December 27, 2024, a comprehensive search was conducted in the Web of Science Core Collection (WoSCC) database using keywords associated with frailty in AD. Bibliometric and knowledge mapping analyses were carried out using CiteSpace, VOSviewer, and R software.
Results
Between 2005 and 2024, a total of 915 publications on frailty in AD were produced by 5950 researchers from 2084 institutions spanning 70 countries. Recent research in this field predominantly focuses on disciplines such as molecular biology, neuroscience, and pharmacology. Current studies emphasize interventions for frailty in patients with AD and the investigation of underlying pathological mechanisms, particularly concerning nutritional status and the influence of long COVID on frailty in AD. Emerging research themes include intervention strategies, mouse models, effects of long COVID, nutritional factors, mechanistic studies, brain fog, and subjective cognitive decline.
Conclusions
This bibliometric analysis highlights research frontiers on frailty in AD, emphasizing early monitoring and management of frailty are pivotal approaches to decelerate AD progression and improve patient outcomes. These findings offer valuable insights for future research, helping to address critical needs in patient care and disease management.
MarinaroFMorvanCAuR, et al.The early detection of neurodegenerative diseases initiative: an international and multidisciplinary effort for transforming the early detection of dementia-causing diseases. Alzheimers Dement2023; 19: e062434.
3.
2024 Alzheimer's disease facts and figures. Alzheimers Dement2024; 20: 3708–3821.
4.
Petermann-RochaFLyallDMGraySR, et al.Associations between physical frailty and dementia incidence: a prospective study from UK Biobank. Lancet Healthy Longev2020; 1: e58–e68.
5.
DengYWangHGuK, et al.Alzheimer's disease with frailty: prevalence, screening, assessment, intervention strategies and challenges. Biosci Trends2023; 17: 283–292.
6.
ChenJHShihHSTuJ, et al.A longitudinal study on the association of interrelated factors among frailty dimensions, cognitive domains, cognitive frailty, and all-cause mortality. J Alzheimers Dis2021; 84: 1795–1809.
7.
GuoCYSunZTanCC, et al.Multi-concept frailty predicts the late-life occurrence of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies. Front Aging Neurosci2022; 14: 855553.
8.
MassaFMarroigAMuniz-TerreraG, et al.Assessment of the link between frailty and dementia in the oldest-olds using joint models. Innov Aging2023; 7: 866–867.
9.
JangJJungHShinJ, et al.Assessment of frailty index at 66 years of age and association with age-related diseases, disability, and death over 10 years in Korea. JAMA Netw Open2023; 6: e2248995.
10.
ChuWChangSFHoHY. Adverse health effects of frailty: systematic review and meta-analysis of middle-aged and older adults with implications for evidence-based practice. Worldviews Evid Based Nurs2021; 18: 282–289.
11.
MusumeciGCiveraS. Does frailty should stop us now?Catheter Cardiovasc Interv2023; 101: 1166–1167.
12.
DoodyPLordJMGreigCA, et al.Frailty: pathophysiology, theoretical and operational definition(s), impact, prevalence, management and prevention, in an increasingly economically developed and ageing world. Gerontology2023; 69: 927–945.
13.
EkramARyanJEspinozaSE, et al.The association between frailty and dementia-free and physical disability-free survival in community-dwelling older adults. Gerontology2023; 69: 549–560.
14.
ParkCMSisonSDMMcCarthyEP, et al.Claims-based frailty index as a measure of dementia severity in medicare claims data. J Gerontol A Biol Sci Med Sci2023; 78: 2145–2151.
15.
LiuKYMukadamN. Frailty and dementia: what can the body tell us about the brain?Int Psychogeriatr2021; 33: 1001–1003.
16.
SunYKoyamaYShimadaS. Inflammation from peripheral organs to the brain: how does systemic inflammation cause neuroinflammation?Front Aging Neurosci2022; 14: 903455.
17.
López-OtínCBlascoMAPartridgeL, et al.Hallmarks of aging: an expanding universe. Cell2023; 186: 243–278.
18.
FabrícioDMChagasMHNDinizBS. Frailty and cognitive decline. Transl Res2020; 221: 58–64.
19.
DibelloVLozuponeMManfrediniD, et al.Oral frailty and neurodegeneration in Alzheimer's disease. Neural Regen Res2021; 16: 2149–2153.
20.
Esteban-CornejoIHoFKPetermann-RochaF, et al.Handgrip strength and all-cause dementia incidence and mortality: findings from the UK Biobank prospective cohort study. J Cachexia Sarcopenia Muscle2022; 13: 1514–1525.
21.
TessierAJWingSSRahmeE, et al.Association of low muscle mass with cognitive function during a 3-year follow-up among adults aged 65 to 86 years in the Canadian longitudinal study on aging. JAMA Netw Open2022; 5: e2219926.
22.
PanzaFSolfrizziVSardoneR, et al.Depressive and biopsychosocial frailty phenotypes: impact on late-life cognitive disorders. J Alzheimers Dis2023; 94: 879–898.
23.
ArosioBRossiPDFerriE, et al.Characterization of vitamin D status in older persons with cognitive impairment. Nutrients2022; 14: 1142.
24.
RahmanMMMimSAIslamMR, et al.Exploring the recent trends in management of dementia and frailty: focus on diagnosis and treatment. Curr Med Chem2022; 29: 5289–5314.
25.
NanriHWatanabeDYoshidaT, et al.Adequate protein intake on comprehensive frailty in older adults: Kyoto-Kameoka study. J Nutr Health Aging2022; 26: 161–168.
26.
KonglevollDMHjartakerAHopstockLA, et al.Protein intake and the risk of pre-frailty and frailty in Norwegian older adults. The Tromso study 1994–2016. J Frailty Aging2022; 11: 256–266.
27.
Coelho-JuniorHJCalvaniRPiccaA, et al.Protein intake and frailty in older adults: a systematic review and meta-analysis of observational studies. Nutrients2022; 14: 2767.
28.
DonthuNKumarSMukherjeeD, et al.How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res2021; 133: 285–296.
29.
XuWXuZGuoY, et al.Two decades of research on the role of diet in Alzheimer's disease (2003–2023): a bibliometric and visual analysis based on CiteSpace. J Health Popul Nutr2024; 43: 9.
30.
KongFWuTDaiJ, et al.Knowledge domains and emerging trends of Genome-wide association studies in Alzheimer's disease: a bibliometric analysis and visualization study from 2002 to 2022. PLoS One2024; 19: e0295008.
31.
CaiHDuRYangK, et al.Bibliometric analysis of the research status and global trends in behavioral and psychological symptoms of dementia in Alzheimer's disease from 2002 to 2022. Curr Neuropharmacol2024; 22: 1720–1732.
32.
ZhangNQuXKangL, et al.Mapping knowledge landscapes and emerging trends of the links between frailty and heart failure: a bibliometric analysis from 2000 to 2023. Cureus2024; 16: e60511.
33.
YuanGYangYLinY, et al.Current status and development trends in CKD with frailty research from 2000 to 2021: a bibliometric analysis. Ren Fail2024; 46: 2292142.
34.
WangHChenXZhengM, et al.Research status and hotspots of social frailty in older adults: a bibliometric analysis from 2003 to 2022. Front Aging Neurosci2024; 16: 1409155.
35.
GuoZWangFXuJ, et al.Knowledge mapping of frailty and surgery: a bibliometric and visualized analysis. Langenbecks Arch Surg2024; 409: 290.
36.
ChenCIbekwe-SanJuanFHouJ. The structure and dynamics of cocitation clusters: a multiple-perspective cocitation analysis. J Am Soc Inf Sci Technol2010; 61: 1386–1409.
37.
ChenCSongM. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One2019; 14: e0223994.
38.
ChenCM. Citespace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol2006; 57: 359–377.
39.
van EckNJWaltmanL. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics2010; 84: 523–538.
40.
PunSSantosAFSaxenaS, et al.Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci2006; 9: 408–419.
41.
RobertsonDASavvaGMKennyRA. Frailty and cognitive impairment–a review of the evidence and causal mechanisms. Ageing Res Rev2013; 12: 840–851.
42.
FranceschiCGaragnaniPMorsianiC, et al.The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne)2018; 5: 61.
43.
DearyIJWhitemanMCStarrJM, et al.The impact of childhood intelligence on later life: following up the Scottish mental surveys of 1932 and 1947. J Pers Soc Psychol2004; 86: 130–147.
44.
GraffJReiDGuanJS, et al.An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature2012; 483: 222–226.
45.
MatthewsFEArthurABarnesLE, et al.A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the cognitive function and ageing study I and II. Lancet2013; 382: 1405–1412.
46.
MichaudMBalardyLMoulisG, et al.Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc2013; 14: 877–882.
47.
Conchillo-SoleOde GrootNSAvilesFX, et al.AGGRESCAN: a server for the prediction and evaluation of “hot spots” of aggregation in polypeptides. BMC Bioinformatics2007; 8: 65.
48.
KnowlesTPVendruscoloMDobsonCM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol2014; 15: 384–396.
49.
FerrucciLGuralnikJMStudenskiS, et al.Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc2004; 52: 625–634.
50.
Cruz-JentoftAJBahatGBauerJ, et al.Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing2019; 48: 601.
51.
JaegerJ. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol2018; 38: 513–519.
52.
KojimaGTaniguchiYIliffeS, et al.Frailty as a predictor of Alzheimer disease, vascular dementia, and all dementia among community-dwelling older people: a systematic review and meta-analysis. J Am Med Dir Assoc2016; 17: 881–888.
53.
BoylePABuchmanASWilsonRS, et al.Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc2010; 58: 248–255.
54.
Jack JrCRBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
55.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet2020; 396: 413–446.
56.
HoogendijkEOAfilaloJEnsrudKE, et al.Frailty: implications for clinical practice and public health. Lancet2019; 394: 1365–1375.
57.
EllegaardOWallinJA. The bibliometric analysis of scholarly production: how great is the impact?Scientometrics2015; 105: 1809–1831.
58.
MuntsantAGimenez-LlortL. Crosstalk of Alzheimer's disease-phenotype, HPA axis, splenic oxidative stress and frailty in late-stages of dementia, with special concerns on the effects of social isolation: a translational neuroscience approach. Front Aging Neurosci2022; 14: 969381.
59.
AlvaradoJCFuentes-SantamariaVJuizJM. Frailty syndrome and oxidative stress as possible links between age-related hearing loss and Alzheimer's disease. Front Neurosci2021; 15: 816300.
60.
PomilioABVitaleAALazarowskiAJ. COVID-19 and Alzheimer's disease: neuroinflammation, oxidative stress, ferroptosis, and mechanisms involved. Curr Med Chem2023; 30: 3993–4031.
61.
SaliniSRussoADe MatteisG, et al.Frailty in elderly patients with COVID-19: a narrative review. Gerontol Geriatr Med2022; 8: 23337214221079956.
62.
SaragihIDAdvaniSSaragihIS, et al.Frailty as a mortality predictor in older adults with COVID-19: a systematic review and meta-analysis of cohort studies. Geriatr Nurs2021; 42: 983–992.
63.
YutaniRVenketaramanVSherenN. Treatment of acute and long-COVID, diabetes, myocardial infarction, and Alzheimer's disease: the potential role of a novel nano-compound-the transdermal glutathione-cyclodextrin complex. Antioxidants (Basel)2024; 13: 1106.
64.
GuoPBenito BallesterosAYeungSP, et al.COVCOG 2: cognitive and memory deficits in long COVID: a second publication from the COVID and cognition study. Front Aging Neurosci2022; 14: 804937.
65.
MudgalSKGaurRRulaniyaS, et al.Pooled prevalence of long COVID-19 symptoms at 12 months and above follow-up period: a systematic review and meta-analysis. Cureus2023; 15: e36325.
66.
MichelenMManoharanLElkheirN, et al.Characterising long COVID: a living systematic review. BMJ Glob Health2021; 6: e005427.
67.
BowyerRCEHugginsCTomsR, et al.Characterising patterns of COVID-19 and long COVID symptoms: evidence from nine UK longitudinal studies. Eur J Epidemiol2023; 38: 199–210.
68.
Al-HakeimHKAl-RubayeHTAlmullaAF, et al.Chronic fatigue, depression and anxiety symptoms in long COVID are strongly predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection. J Clin Med2023; 12: 511.
69.
TheoharidesTCKempurajD. Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID. Cells2023; 12: 688.
70.
TrueickRGodson-TreacyMDonnellyT. 63 Frailty and COVID-19 in hospitalised older adults. Age Ageing2022; 51: afac218.049.
71.
DamantiSCillaMCilonaM, et al.Prevalence of long COVID-19 symptoms after hospital discharge in frail and robust patients. Front Med (Lausanne)2022; 9: 834887.
72.
LiuLNiSYYanW, et al.Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: a systematic review, meta-analysis and call for action. EClinicalMedicine2021; 40: 101111.
73.
SmadiMKaburisMSchnapperY, et al.SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses. Br J Psychiatry2023; 223: 348–361.
74.
VrillonAMhannaEAveneauC, et al.COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients. Alzheimers Res Ther2021; 13: 77.
75.
MorettiRCarusoPGiuffreM, et al.COVID-19 lockdown effect on not institutionalized patients with dementia and caregivers. Healthcare (Basel)2021; 9: 893.
76.
MatsuiTMitsumaSNagataA, et al.Accelerated cognitive decline after the COVID-19 pandemic in a community population of older persons with cognitive impairment: a 4-year time series analysis in the Tokyo metropolis area. Geriatr Gerontol Int2023; 23: 200–204.
77.
PerryG. Alzheimer's disease patients in the crosshairs of COVID-19. J Alzheimers Dis2020; 76: 1.
78.
WangLDavisPBVolkowND, et al.Association of COVID-19 with new-onset Alzheimer's disease. J Alzheimers Dis2022; 89: 411–414.
79.
RahmatiMYonDKLeeSW, et al.New-onset neurodegenerative diseases as long-term sequelae of SARS-CoV-2 infection: a systematic review and meta-analysis. J Med Virol2023; 95: e28909.
80.
MarcusR. New Alzheimer disease drugs, long COVID and the central nervous system, and a nasal spray for migraines-highlights from the 2023 American academy of neurology conference. JAMA2023; 329: 1811–1813.
81.
PszczolowskaMWalczakKMiskowW, et al.Molecular cross-talk between long COVID-19 and Alzheimer's disease. Geroscience2024; 46: 2885–2899.
82.
NaughtonSXRavalUPasinettiGM. Potential novel role of COVID-19 in Alzheimer's disease and preventative mitigation strategies. J Alzheimers Dis2020; 76: 21–25.
83.
Chaves-FilhoAMBraniffOAngelovaA, et al.Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome. Brain Res Bull2023; 201: 110702.
84.
StefanoGBButtikerPWeissenbergerS, et al.Biomedical perspectives of acute and chronic neurological and neuropsychiatric sequelae of COVID-19. Curr Neuropharmacol2022; 20: 1229–1240.
85.
BaranovaACaoHZhangF. Causal effect of COVID-19 on Alzheimer's disease: a Mendelian randomization study. J Med Virol2023; 95: e28107.
86.
ArosioBCalvaniRFerriE, et al.Sarcopenia and cognitive decline in older adults: targeting the muscle-brain axis. Nutrients2023; 15: 1853.
87.
PonvelPShaharSSinghDKA, et al.Multidomain intervention for reversal of cognitive frailty, towards a personalized approach (AGELESS trial): study design. J Alzheimers Dis2021; 82: 673–687.
88.
ManganottiPMicheluttiMFurlanisG, et al.Deficient GABABergic and glutamatergic excitability in the motor cortex of patients with long-COVID and cognitive impairment. Clin Neurophysiol2023; 151: 83–91.
89.
ChuNMXueQLMcAdams-DeMarcoMA, et al.Frailty-a risk factor of global and domain-specific cognitive decline among a nationally representative sample of community-dwelling older adult U.S. Medicare Beneficiaries.Age Ageing2021; 50: 1569–1577.
90.
WallaceLHunterSTheouO, et al.Frailty and neuropathology in relation to dementia status: the Cambridge city over-75s cohort study. Int Psychogeriatr2021; 33: 1035–1043.
91.
GuanDXRockwoodKSmithEE, et al.Sex moderates the association between frailty and mild behavioral impairment. J Prev Alzheimers Dis2022; 9: 692–700.
92.
YangHJLeeSKohMJ, et al.The association of white matter hyperintensities with frailty in patients with very mild to moderate Alzheimer's disease. J Alzheimers Dis2021; 83: 1281–1289.
93.
KaramacoskaDButtALeungIHK, et al.Brain function effects of exercise interventions for cognitive decline: a systematic review and meta-analysis. Front Neurosci2023; 17: 1127065.
94.
RoySKWangJJXuYM. Effects of exercise interventions in Alzheimer's disease: a meta-analysis. Brain Behav2023; 13: e3051.
95.
Coelho-JúniorHJUchidaMC. Effects of low-speed and high-speed resistance training programs on frailty status, physical performance, cognitive function, and blood pressure in prefrail and frail older adults. Front Med (Lausanne)2021; 8: 702436.
96.
CezarNOCAnsaiJHde AndradeLP. Home-based multimodal exercise program in older people with Alzheimer disease: randomized controlled trial protocol. Physiother Res Int2021; 26: e1899.
97.
CezarNOCAprahamianIAnsaiJH, et al.Feasibility of reducing frailty components in older adults with Alzheimer's dementia: a randomized controlled home-based exercise trial (AD-HOMEX). Exp Gerontol2021; 150: 111390.
98.
LiangYJSuQWShengZR, et al.Effectiveness of physical activity interventions on cognition, neuropsychiatric symptoms, and quality of life of Alzheimer's disease: an update of a systematic review and meta-analysis. Front Aging Neurosci2022; 14: 830824.
99.
WangYYYangLZhangJ, et al.The effect of cognitive intervention on cognitive function in older adults with Alzheimer's disease: a systematic review and meta-analysis. Neuropsychol Rev2022; 32: 247–273.
100.
Mustafa KhalidNHaronHShaharS, et al.Current evidence on the association of micronutrient malnutrition with mild cognitive impairment, frailty, and cognitive frailty among older adults: a scoping review. Int J Env Res Public Health2022; 19: 15722.
101.
UnsalPGunerMOzsurekciC, et al.Prevalence of nutrition disorders and nutrition-related conditions in older patients with Alzheimer's disease. Nutr Clin Pract2023; 38: 1142–1153.
102.
KlimovaBNovotnyMSchlegelP, et al.The effect of Mediterranean diet on cognitive functions in the elderly population. Nutrients2021; 13: 2067.
103.
SeibertMMuhlbauerVHolbrookJ, et al.Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials. Alzheimers Res Ther2021; 13: 131.
104.
SakuraiTSugimotoTAkatsuH, et al.Japan-multimodal intervention trial for the prevention of dementia: a randomized controlled trial. Alzheimers Dement2024; 20: 3918–3930.
105.
XuXChewKAWongZX, et al.The SINgapore GERiatric intervention study to reduce cognitive decline and physical frailty (SINGER): study design and protocol. J Prev Alzheimers Dis2022; 9: 40–48.
106.
RoachJCRapozoMKHaraJ, et al.A remotely coached multimodal lifestyle intervention for Alzheimer's disease ameliorates functional and cognitive outcomes. J Alzheimers Dis2023; 96: 591–607.
107.
PatelHMartinezPPerkinsA, et al.Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol Aging2022; 109: 52–63.
108.
CaradonnaENemniRBifoneA, et al.The brain-gut axis, an important player in Alzheimer and Parkinson disease: a narrative review. J Clin Med2024; 13: 4130.
109.
DacomoLLa VitolaPBrunelliL, et al.Transcriptomic and metabolomic changes might predict frailty in SAMP8 mice. Aging Cell2024; 23: e14263.
110.
WestiEWMolhemiSHansenCT, et al.Comprehensive analysis of the 5xFAD mouse model of Alzheimer's disease using dMRI, immunohistochemistry, and neuronal and glial functional metabolic mapping. Biomolecules2024; 14: 1294.
111.
GendronWHFertanEPelletierS, et al.Age related weight loss in female 5xFAD mice from 3 to 12 months of age. Behav Brain Res2021; 406: 113214.
112.
ZhongMZPengTDuarteML, et al.Updates on mouse models of Alzheimer's disease. Mol Neurodegener2024; 19: 23.
113.
Castillo-MariqueoLGimenez-LlortL. Translational modeling of psychomotor function in normal and AD-pathological aging with special concerns on the effects of social isolation. Front Aging2021; 2: 648567.
114.
Baglietto-VargasDFreudeKKGarcia-LeonJA. Animal and cellular models of Alzheimer's disease. Biomedicines2024; 12: 1308.
115.
MusazziLCariniGBarbieriSS, et al.Phenotypic frailty assessment in SAMP8 mice: sex differences and potential role of miRNAs as peripheral biomarkers. J Gerontol A Biol Sci Med Sci2023; 78: 1935–1943.
116.
Castillo-MariqueoLGiménez-LlortL. Impact of behavioral assessment and re-test as functional trainings that modify survival, anxiety and functional profile (physical endurance and motor learning) of old male and female 3xTg-AD mice and NTg mice with normal aging. Biomedicines2022; 10: 973.
117.
RodaEPrioriECRattoD, et al.Neuroprotective metabolites of hericium erinaceus promote neuro-healthy aging. Int J Mol Sci2021; 22: 6379.
118.
GendronWHFertanERoddickKM, et al.Intranasal insulin treatment ameliorates spatial memory, muscular strength, and frailty deficits in 5xFAD mice. Physiol Behav2024; 281: 114583.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
